{"title":"内脏脂肪作为原发性醛固酮增多症患者新发糖尿病的预测因子:一项队列研究。","authors":"Wen-Kai Chu, Leay Kiaw Er, Chin-Chen Chang, Jin-Ying Lu, Wan-Chen Wu, Yao-Chou Tsai, Yen-Hung Lin, Vin-Cent Wu","doi":"10.1177/20406223241301892","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with primary aldosteronism (PA) exhibit a high prevalence of diabetes mellitus (DM). However, the relationship between visceral adipose tissue (VAT) and new-onset diabetes mellitus (NODM) in PA patients remains unclear.</p><p><strong>Objectives: </strong>To explore the association between VAT and the risk of NODM in PA patients.</p><p><strong>Design: </strong>This is a prospective cohort study spanning 10 years (2010-2020).</p><p><strong>Methods: </strong>A total of 342 PA patients were enrolled prospectively. Abdominal adiposity indexes, including VAT area, VAT ratio, subcutaneous adipose tissue (SAT) area, and SAT ratio, were measured using a computed tomography-based software at diagnosis.</p><p><strong>Results: </strong>Of 342 PA patients (46.2% male, mean age 50.8 ± 11.2 years), 35 (10.2%) developed NODM over a mean follow-up of 7.4 years. A positive nonlinear association between NODM risk and Log (VAT ratio) ⩾ -0.72 was observed (high-VAT group). High VAT (odds ratio (OR), 6.09; <i>p</i> = 0.005), older age (OR, 1.09; <i>p</i> < 0.001), higher body mass index (OR, 1.24; <i>p</i> < 0.001), higher waist-to-hip ratio (OR, 1.11, <i>p</i> < 0.001), lower baseline aldosterone (OR, 0.99, <i>p</i> = 0.011), higher diastolic blood pressure (OR, 1.05, <i>p</i> = 0.012), and lower systolic blood pressure (OR, 0.98, <i>p</i> = 0.045) as risk factors for high VAT. Adrenalectomy did not significantly associate with reduced NODM risk (OR, 0.49; <i>p</i> = 0.292).</p><p><strong>Conclusion: </strong>Our findings highlight that 10.2% of PA patients develop NODM over a mean follow-up of 7.4 years, with high VAT increasing the risk. Baseline VAT is a key determinant of NODM development in PA patients, regardless of targeted treatments.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"15 ","pages":"20406223241301892"},"PeriodicalIF":3.3000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607768/pdf/","citationCount":"0","resultStr":"{\"title\":\"Visceral adiposity as a predictor of new-onset diabetes in patients with primary aldosteronism: a cohort study.\",\"authors\":\"Wen-Kai Chu, Leay Kiaw Er, Chin-Chen Chang, Jin-Ying Lu, Wan-Chen Wu, Yao-Chou Tsai, Yen-Hung Lin, Vin-Cent Wu\",\"doi\":\"10.1177/20406223241301892\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Patients with primary aldosteronism (PA) exhibit a high prevalence of diabetes mellitus (DM). However, the relationship between visceral adipose tissue (VAT) and new-onset diabetes mellitus (NODM) in PA patients remains unclear.</p><p><strong>Objectives: </strong>To explore the association between VAT and the risk of NODM in PA patients.</p><p><strong>Design: </strong>This is a prospective cohort study spanning 10 years (2010-2020).</p><p><strong>Methods: </strong>A total of 342 PA patients were enrolled prospectively. Abdominal adiposity indexes, including VAT area, VAT ratio, subcutaneous adipose tissue (SAT) area, and SAT ratio, were measured using a computed tomography-based software at diagnosis.</p><p><strong>Results: </strong>Of 342 PA patients (46.2% male, mean age 50.8 ± 11.2 years), 35 (10.2%) developed NODM over a mean follow-up of 7.4 years. A positive nonlinear association between NODM risk and Log (VAT ratio) ⩾ -0.72 was observed (high-VAT group). High VAT (odds ratio (OR), 6.09; <i>p</i> = 0.005), older age (OR, 1.09; <i>p</i> < 0.001), higher body mass index (OR, 1.24; <i>p</i> < 0.001), higher waist-to-hip ratio (OR, 1.11, <i>p</i> < 0.001), lower baseline aldosterone (OR, 0.99, <i>p</i> = 0.011), higher diastolic blood pressure (OR, 1.05, <i>p</i> = 0.012), and lower systolic blood pressure (OR, 0.98, <i>p</i> = 0.045) as risk factors for high VAT. Adrenalectomy did not significantly associate with reduced NODM risk (OR, 0.49; <i>p</i> = 0.292).</p><p><strong>Conclusion: </strong>Our findings highlight that 10.2% of PA patients develop NODM over a mean follow-up of 7.4 years, with high VAT increasing the risk. Baseline VAT is a key determinant of NODM development in PA patients, regardless of targeted treatments.</p>\",\"PeriodicalId\":22960,\"journal\":{\"name\":\"Therapeutic Advances in Chronic Disease\",\"volume\":\"15 \",\"pages\":\"20406223241301892\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607768/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Chronic Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20406223241301892\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Chronic Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406223241301892","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景:原发性醛固酮增多症(PA)患者表现出糖尿病(DM)的高患病率。然而,内脏脂肪组织(VAT)与PA患者新发糖尿病(NODM)之间的关系尚不清楚。目的:探讨PA患者VAT与NODM风险的关系。设计:这是一项为期10年(2010-2020)的前瞻性队列研究。方法:前瞻性纳入342例PA患者。在诊断时使用基于计算机断层扫描的软件测量腹部脂肪指数,包括VAT面积、VAT比率、皮下脂肪组织(SAT)面积和SAT比率。结果:在342例PA患者中(46.2%为男性,平均年龄50.8±11.2岁),35例(10.2%)在平均7.4年的随访中发展为NODM。观察到NODM风险和Log(增值税比率)大于或等于-0.72之间的正非线性关联(高增值税组)。高增值税(优势比(OR), 6.09;p = 0.005)、年龄较大(OR, 1.09;p p p p = 0.011),舒张压升高(OR, 1.05, p = 0.012)和收缩压降低(OR, 0.98, p = 0.045)是高增值税的危险因素。肾上腺切除术与降低NODM风险无显著相关性(OR, 0.49;p = 0.292)。结论:我们的研究结果强调,10.2%的PA患者在平均7.4年的随访中发展为NODM,高VAT增加了风险。无论靶向治疗如何,基线VAT是PA患者NODM发展的关键决定因素。
Visceral adiposity as a predictor of new-onset diabetes in patients with primary aldosteronism: a cohort study.
Background: Patients with primary aldosteronism (PA) exhibit a high prevalence of diabetes mellitus (DM). However, the relationship between visceral adipose tissue (VAT) and new-onset diabetes mellitus (NODM) in PA patients remains unclear.
Objectives: To explore the association between VAT and the risk of NODM in PA patients.
Design: This is a prospective cohort study spanning 10 years (2010-2020).
Methods: A total of 342 PA patients were enrolled prospectively. Abdominal adiposity indexes, including VAT area, VAT ratio, subcutaneous adipose tissue (SAT) area, and SAT ratio, were measured using a computed tomography-based software at diagnosis.
Results: Of 342 PA patients (46.2% male, mean age 50.8 ± 11.2 years), 35 (10.2%) developed NODM over a mean follow-up of 7.4 years. A positive nonlinear association between NODM risk and Log (VAT ratio) ⩾ -0.72 was observed (high-VAT group). High VAT (odds ratio (OR), 6.09; p = 0.005), older age (OR, 1.09; p < 0.001), higher body mass index (OR, 1.24; p < 0.001), higher waist-to-hip ratio (OR, 1.11, p < 0.001), lower baseline aldosterone (OR, 0.99, p = 0.011), higher diastolic blood pressure (OR, 1.05, p = 0.012), and lower systolic blood pressure (OR, 0.98, p = 0.045) as risk factors for high VAT. Adrenalectomy did not significantly associate with reduced NODM risk (OR, 0.49; p = 0.292).
Conclusion: Our findings highlight that 10.2% of PA patients develop NODM over a mean follow-up of 7.4 years, with high VAT increasing the risk. Baseline VAT is a key determinant of NODM development in PA patients, regardless of targeted treatments.
期刊介绍:
Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area.